

## IN THE CLAIMS

Cancel claim 40 without prejudice or disclaimer.

Please amend claims 1, 21, 41, 42, 44, and 46-50 as follows:

In claim 1, lines 2-3, after "parenteral nutrition, a", delete "nutrient" and insert -- nutritively effective --.

- C1  
Sub  
F21
21. (twice amended) The method of claim 1 wherein the [administration of the] insulinotropic peptide or peptides [produces a blood level of the peptides in the range of 1 pmol per L to 1 nmol per L of blood plasma] are administered at a rate of 0.01 to 50 pmol per kg of body weight of patient per minute. (infusion only)

- C2  
Sub  
D1
41. (amended) A method of enhancing [metabolic disposal] metabolism of nutrients, comprising administering by a parenteral route to a non-diabetic patient in need of enhancing [metabolic disposal] metabolism of nutrients a [nutrient] nutritively effective composition comprising one or more nutrients or any combination thereof and one or more insulinotropic peptide or peptides, wherein said peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1(7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the D-terminus ketones thereof, the N-terminus modifications thereof, organic molecular mimics of the insulinotropic peptides which fit the insulinotropic receptor sites, or any mixture thereof.

- Sub  
F3
42. (amended) A method of enhancing [metabolic disposal] metabolism of nutrients, comprising administering by a parenteral route to a patient with a disturbed glucose metabolism, a surgery patient, a comatose patient, a patient in shock, a patient with gastrointestinal disease, a patient with digestive hormone disease, an obese patient, an atherosclerotic patient, a patient with vascular disease, a patient with gestational diabetes, a patient with liver disease, a patient with liver cirrhosis, a patient with glucocorticoid excess, a patient with Cushings disease, a

C2  
cancel

patient with activated counterregulatory hormones that occur after trauma or a disease, a patient with hypertriglyceridemia, or a patient with chronic pancreatitis, a [nutrient] nutritively effective composition comprising one or more nutrients or any combination thereof and one or more insulintropic peptides.

---

- C3  
SUB  
D2
44. (amended) A method of enhancing [metabolic disposal] metabolism of nutrients, comprising administering by a parenteral route to a patient in need of enhancing [metabolic disposal] metabolism of nutrients a [nutrient] nutritively effective composition comprising glucose and one or more insulintropic peptide or peptides, wherein said insulintropic peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1(7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the D-terminus ketones thereof, the N-terminus modifications thereof, organic molecular mimics of the insulintropic peptides which fit the insulintropic receptor sites, or any mixture thereof.
- 

In claim 46, line 2, after "hyperglycemic patient", insert -- a nutritively effective amount of --.

---

- C4
47. (amended) The method of claim 2, wherein the carbohydrate is a glucose, fructose, galactose, xylitol, mannitol, sorbitol[, a derivative of any of said carbohydrates], or any combination thereof.
48. (amended) The method of claim 1 wherein said nutrient is one or more amino acids, lipids, free fatty acids, mono- or diglycerides or glycerol[, a derivative of any of said nutrients], or any combination thereof.
49. (amended) The method of claim [2] 1, wherein said [carbohydrate] nutrient is a pyruvate.